TORONTO, Jan. 25, 2015 /CNW/ - Bedrocan Canada Inc.
("Bedrocan Canada", "Company"), wholly‑owned subsidiary of Canopy
Growth Corporation ("Canopy Growth") (TSXV: CGC) has made medical
cannabis more affordable for all Canadian patients with a new price
structure called True Compassionate Pricing. Under
True Compassionate Pricing, all six cannabis varieties
produced by Bedrocan Canada will be priced at $5 per gram, making it the most affordable
product line in Canada.
Many Canadians who medicate with cannabis are doing so because
traditional pharmaceutical drugs have not been as effective at
treating their symptoms or have undesirable side effects. The
decision to consume medical cannabis is made more complex due to
the cost of the medicine.
"With limited insurance coverage and taxation, the affordability
of medical cannabis can be a significant barrier to chronically ill
patients obtaining the benefits of a medical marijuana program,"
said Jonathan Zaid, Member of
Bedrocan Canada's Patient Advisory Board and Executive
Director of Canadians for Fair Access to Medical Marijuana. "With
its True Compassionate Pricing, Bedrocan is helping patients
by making their medicine more affordable."
Bedrocan Canada currently produces six standardized whole-flower
cannabis varieties that provide consistency and reliability to
people managing a variety of medical conditions and symptoms. All
strains are covered by the True Compassion Pricing promise
and are guaranteed to be in stock.
"Bedrocan Canada's production methods have been refined over two
decades to maximize yield and eliminate genetic variance from
harvest to harvest. Because of that we're able to produce
standardized varieties efficiently," said Marc Wayne, President of Bedrocan Canada. "Now
that our Toronto facility is
operating at full capacity, we are in a position to offer lower
prices to our clients, the vast majority of whom are paying out of
pocket for their medication."
Bedrocan Canada continues its active dialogue with the insurance
industry to enhance insurance eligibility for medical cannabis and
medical cannabis devices. The Company is also encouraging the
patient community to write to the federal government in an effort
to change the current applicability of sales tax to medical
cannabis, a policy that is inconsistent with the treatment of other
healthcare practitioner authorized medications. Patients can visit
www.bedrocan.ca to download a letter to The Honourable Bill
Morneau, Minister of Finance.
Working collaboratively, Bedrocan Canada strives to make medical
cannabis more affordable for all Canadian patients.
About Bedrocan Canada
Bedrocan Canada is focused on medicinal cannabis production and
research, including, the EQUAL Study, which is currently enrolling
patients and evaluating how cannabis is affecting their quality of
life of Canadian patients. Bedrocan's standardized strains have
been used by thousands of patients in seven countries around the
world. www.bedrocan.ca
About Canopy Growth Corporation
Canopy Growth is Canada's first publicly traded
medical marijuana company and the first geographically diversified
producer with multiple licenses under the Marihuana for Medical
Purposes Regulations. Through its wholly owned subsidiaries, Tweed,
Tweed Farms, and Bedrocan, the Company operates three
state-of-the-art production facilities in Ontario and
distributes marijuana across the country to Canadian patients
managing a host of medical conditions. The Company is dedicated to
educating healthcare practitioners, providing consistent access to
high quality medication, conducting robust clinical research, and
furthering the public's understanding of how marijuana is used for
medical purposes. www.canopygrowth.com
Forward Looking Statement:
This news release contains forward-looking statements.
Often, but not always, forward-looking statements can be identified
by the use of words such as "plans", "expects" or "does not
expect", "is expected", "estimates", "intends", "anticipates" or
"does not anticipate", or "believes", or variations of such words
and phrases or state that certain actions, events or results "may",
"could", "would", "might" or "will" be taken, occur or be
achieved. Forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company or any
of its subsidiaries to be materially different from any future
results, performance or achievements expressed or implied by the
forward-looking statements.
Although Canopy Growth Corp. has attempted to identify important
factors that could cause actual actions, events or results to
differ materially from those described in forward-looking
statements, there may be other factors that cause actions, events
or results not to be as anticipated, estimated or intended. Readers
should not place undue reliance on forward-looking statements. The
factors identified above are not intended to represent a complete
list of the factors that could affect the Company or any of its
subsidiaries. The forward-looking statements included in this news
release are made as of the date of this news release and Canopy
Growth Corp. does not undertake an obligation to publicly update
such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable
securities legislation.
SOURCE Canopy Growth Corporation